粘蛋白-1：一个有前景的泛癌治疗靶点。
Mucin-1: a promising pan-cancer therapeutic target.
作者信息
Grewal Udhayvir Singh, Kurzrock Razelle
机构信息
Division of Hematology, Oncology, Blood and Marrow Transplantation, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.
Division of Medical Oncology, Medical College of Wisconsin Froedtert Cancer Center, Milwaukee, WI, USA.
出版信息
NPJ Precis Oncol. 2025 Jul 2;9(1):218. doi: 10.1038/s41698-025-01016-2.
Mucin1 or MUC1 (also known as CD227, EMA, MCD, MAM6, PEM, PUM, KL-6, CA 27.29/CA 15-3) is a highly glycosylated transmembrane mucin family member protein that is overexpressed in various solid or hematological cancers. Abnormal MUC1 expression/glycosylation in cancer leads to the activation of multiple pathways, resulting in tumor migration, invasion and accelerated growth. CA 27.29/CA 15-3 are blood tumor markers used in breast cancer patients. Novel therapeutic agents targeting MUC1, including cancer vaccines, cellular therapies, radiopharmaceuticals, monoclonal antibodies and antibody-drug conjugates, are being explored in clinical studies. The current review summarizes the molecular mechanisms of MUC1 in cancer and highlights existing data for MUC1-targeting agents in the therapeutic pipeline.
黏蛋白1或MUC1（也称为CD227、上皮膜抗原、MCD、MAM6、PEM、PUM、KL-6、CA 27.29/CA 15-3）是一种高度糖基化的跨膜黏蛋白家族成员蛋白，在各种实体癌或血液系统癌症中过表达。癌症中MUC1表达/糖基化异常会导致多种信号通路激活，从而引起肿瘤迁移、侵袭和加速生长。CA 27.29/CA 15-3是用于乳腺癌患者的血液肿瘤标志物。目前正在临床研究中探索针对MUC1的新型治疗药物，包括癌症疫苗、细胞疗法、放射性药物、单克隆抗体和抗体药物偶联物。本综述总结了MUC1在癌症中的分子机制，并重点介绍了治疗研发中针对MUC1药物的现有数据。
Zotero 插件